Interferon Kappa
Also known as: IFN-κ, IFNK, Interferon kappa, Interferon‑κ
Source Interferon Kappa at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Interferon kappa (IFNK) is a low‑abundance type I interferon expressed primarily in epithelial cells. It signals through the canonical interferon‑α/β receptor to induce antiviral and immune‑regulatory genes, but has not been developed as an approved therapeutic.
Mechanism of Action
Binds the IFNAR1/IFNAR2 receptor complex, activates JAK1/TYK2 kinases, leading to STAT1/STAT2 phosphorylation and induction of interferon-stimulated genes with antiviral and immunomodulatory effects.
Routes of Administration
Goals & Uses
- Antiproliferative / antitumor effectsOncologyLow
- Antiviral therapyInfectious DiseaseLow
- Cancer immunotherapy adjunctOncologyLow
- Autoimmune disease research (SLE/lupus)Immunology / AutoimmunityModerate
- HPV suppressionAntiviralModerate
- Antiviral defense in skinImmunology / AntiviralModerate
Contraindications
- Severe autoimmune disordersAutoimmunityModerate
- Hypersensitivity to type I interferonsAllergy / ImmunologyHigh
Adverse Effects
- Flu-like symptomsSystemic/ImmunologicalUnknown
- Injection site reactionsLocalUnknown
- Immunomodulatory dysregulationImmunologyUnknown
Drug Interactions
- JAK inhibitors (e.g., tofacitinib, ruxolitinib)High
- ImmunosuppressantsModeratePotential interaction with immune pathways or infection risk
Population Constraints
- PregnancyReproductive SafetyRelative
- Pediatric populationAgeRelative
- Patients with active autoimmune diseaseImmunologicalRelative
Regulatory Status
- European UnionUnapprovedNo marketing authorization.
- United StatesUnapprovedInvestigational only.
- United KingdomUnapprovedNo MHRA-approved therapeutic product. Research use only.
No regulatory approval; investigated in preclinical and early‑phase research for antiviral and anticancer applications.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Interferon Kappa?
Interferon kappa (IFNK) is a low‑abundance type I interferon expressed primarily in epithelial cells. It signals through the canonical interferon‑α/β receptor to induce antiviral and immune‑regulatory genes, but has not been developed as an approved therapeutic.
What is Interferon Kappa used for?
Interferon Kappa is educationally associated with: Antiproliferative / antitumor effects, Antiviral therapy, Cancer immunotherapy adjunct, Autoimmune disease research (SLE/lupus), HPV suppression, Antiviral defense in skin. Educational only — not medical advice.
How is Interferon Kappa administered?
Recorded routes of administration: Intravenous, Subcutaneous.
What are the potential side effects of Interferon Kappa?
Reported adverse effects include: Flu-like symptoms, Injection site reactions, Immunomodulatory dysregulation. This list is not exhaustive — consult a qualified clinician.
Who should avoid Interferon Kappa?
Recorded contraindications: Severe autoimmune disorders, Hypersensitivity to type I interferons. Consult a qualified clinician before use.